Ilika raises £0.9m in upsized retail offer

Ilika plc

Further to the announcement by the Company in respect of the Retail Offer dated 22 May 2025, Ilika plc (LON:IKA), has announced that, following the closing of the Retail Offer on the BookBuild platform on 28 May 2025, the Retail Offer was significantly oversubscribed. Accordingly, the Company has elected to increase scale of the Retail Offer to raise total gross proceeds of £0.9 million through the issue of 2,727,273 Retail Offer Shares at the Issue Price of 33 pence per share.

Consequently, it is anticipated that 9,884,017 Placing Shares, 81,819 Director Subscription Shares and 2,727,273 Retail Offer Shares resulting in a total of 12,693,109 New Ordinary Shares being issued in relation to the Fundraising. The total gross monies raised (before expenses) is approximately £4.2 million. The proceeds will be used as outlined in the retail offer announcement dated 22 May 2025 with the excess being proportionately assigned to further advance the commercial status of both of the Company’s product lines.

Allocations were made to existing Shareholders, applying the principles of soft pre-emption.  Given the significant demand, existing Shareholders received 100 per cent. of their soft pre-emptive allowance, when their order matched or exceeded their soft pre-emptive allowance. Where the order was greater than the soft pre-emptive allowance shareholders received c. 89.97 per cent of their additional demand1.

Other than where defined, capitalised terms used in this announcement have the meanings given to them in the Retail Offer Announcement.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company will have 180,802,175 Ordinary Shares in issue with the Company holding no Ordinary Shares in treasury. Therefore, the total number of voting rights will also be 180,802,175. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of Ilika Plc under the FCA’s Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Dr Tom McColm on Ilika: Stereax revenues and Goliath milestones (LON:IKA)

Clean-tech equities specialist Dr Tom McColm reviews Ilika’s interim results, highlighting stable cash levels, the first recurring commercial revenues from Stereax, and continued technical and manufacturing progress on the Goliath battery platform.

Ilika CEO Graeme Purdy on Stereax and Goliath progress (LON:IKA)

Graeme Purdy, CEO of Ilika, outlines progress in manufacturing readiness and early customer shipments for the Stereax miniature solid-state battery, as well as ongoing grant-supported development and customer engagement for the Goliath EV battery programme.

Ilika moves into commercial phase with first Stereax electrode order

Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.

Ilika plc: First Commercial Revenues Signal Pivotal Shift in Solid-State Battery Journey (Video)

Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

Ilika CEO Graeme Purdy shares how the company has shifted from commissioning to customer deliveries of its Stereax batteries — and why its Goliath EV programme is designed to beat the commoditised market with faster charging and extended range.

Ilika reports on-track progress across Stereax and Goliath in H1 2025/26

Ilika reports unaudited half-year results to 31 October 2025, highlighting on-schedule delivery of key commercial milestones across its Stereax medical battery and Goliath EV battery programmes, alongside continued customer validation, pilot-line commissioning, and £4.2m fundraising to support its roadmap.

Search

Search